1 / 15

Statin Induce Myotoxicity

Statin Induce Myotoxicity. นสภ.อัจจิมา บัวหลวงงาม. Risk of myotoxicity. all statins can cause myopathy with a risk of progressing to rhabdomyolysis . The risk appears to increase with higher doses. Lipophilicity >>> hydrophillic lipophilic

ivy-cervantes
Télécharger la présentation

Statin Induce Myotoxicity

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Statin Induce Myotoxicity นสภ.อัจจิมา บัวหลวงงาม

  2. Risk of myotoxicity • all statins can cause myopathy with a risk of progressing to rhabdomyolysis. • The risk appears to increase with higher doses. • Lipophilicity>>>hydrophillic • lipophilic • Atorvastatin, Fluvastatin, Lovastatin, Simvastatin • hydrophilic • Pravastatin, Rosuvastatin

  3. Mechanism HMG-CoA HMG-CoAreductase Statins mevalonate antioxidant and membrane stabilizer that is utilized by mitochondria for electron transport Atrogin-1 ubiquinone (coenzyme Q10) mitochondrial adenosine triphosphate (ATP)

  4. Classification of Muscular Adverse Events Br J Cardiol,2005

  5. Classification of Muscular Adverse Events Br J Cardiol,2005

  6. The American College of Cardiology/American Heart Association/National Heart, Lung, and Blood Institute (ACC/AHA/NHLBI) • 1. Statin myopathy: muscle complaints related to statin drug use • 2. Myalgia: muscle complaints without serum CK elevations • 3. Myositis: muscle symptoms with serum CK elevations • 4. Rhabdomyolysis: markedly elevated CK levels, usually > 10 times ULN, with an elevated creatinine level consistent with pigmentinduced nephropathy J Am Coll Cardiol. 2002; 40: 567-72

  7. สารราชวิทยาลัยอายุรแพทย์ฯสารราชวิทยาลัยอายุรแพทย์ฯ • myopathy • มีอาการกล้ามเนื้ออักเสบร่วมกับระดับของ creatine kinase (CK)>10 เท่า ของ ULN สารราชวิทยาลัยอายุรแพทย์ฯ ปีที่23 ฉบับที่ 3 กรกฎาคม–ธันวาคม 2549

  8. The National Lipid Association • rhabdomyolysis • muscle cell destruction or enzyme leakage, regardless of the CK level when measured, • considered to be causally related to a change in renal function (Thompson et al 2006).

  9. The National Lipid Association • Classify absolute CK elevation • Mild: CK increases < 10 times ULN • Moderate: CK increases ≥ 10 times ULN, and • Severe: CK increases ≥ 50 times the ULN (Thompson et al 2006).

  10. Time to onset • Mean duration of thereapy • 6.3 months (0.25-48 months)

  11. Incidence • Myalgia without changes in CK levels (Bays 2006). • 21 statin-based clinical trials with over 180,000 person years for evidence of muscle toxicity. • The incidence of myopathy was 11 per 100,000 person-years. • The incidence of rhabdomyolysis in 2 cohort studies was 3.4 (1.6–6.5) per 100,000 person-years • 10-fold higher when gemfibrozil was used in combination with statins. • For statins metabolized by CYP3A4 such as lovastatin, atorvastatin, and simvastatin), the incidence was 4.2 per 100,000 person-years. In this group, interaction with drugs known to inhibit CYP3A4 (ie, erythromycin and azoleantifungals) occurred in 60%

  12. The American Journal of Cardiology. Vol 97 (8A) April 17, 2006

  13. The American Journal of Cardiology. Vol 97 (8A) April 17, 2006

  14. Management

  15. Monitor transaminase level • When start Statin or fibrates • After medication 6-12 weeks • Follow up every 1-2 time per year • High dose or more than 2 medication • 3-6 months Guidelines for Management of Dyslipidemia,สารราชวิทยาลัยอายุรแพทย์ฯ 2545

More Related